By Julia Karow
NuGen Technologies said this week that it is expanding its facilities and hiring researchers to develop new sample-prep products for next-generation sequencing.
Next month, the company plans to move into a larger facility in San Carlos, Calif., and to open a new research facility in Seattle.
The Seattle labs will house a team of newly recruited researchers led by Christopher Raymond, who joins NuGen from Rosetta Inpharmatics, a former Merck research subsidiary. Merck sold Rosetta's software business to Microsoft in the spring and its gene expression lab to Covance in the summer.
At Merck, Raymond and his colleagues developed new technologies for whole-transcriptome molecular profiling, targeted genome resequencing, and for the computational analysis of next-generation sequencing data.
By year's end, NuGen plans to launch an RNA-seq sample-preparation kit that allows users to start with less RNA, and plans to add "many more products for NGS in the near future," Raymond said in a statement.
These products will allow customers to convert "a broader range of starting material types into sequencing libraries while streamlining the sample preparation workflow," according to the company.